BMS Pauses Zola-cel Autoimmune Studies

Company: Bristol Myers Squibb / Juno Therapeutics · Asset: Zolacabtagene Autoleucel (Zola-cel / BMS-986353 / CC-97540) · Event: Voluntary Pause of Autoimmune Studies · Date: September 4, 2026 Summary Bristol Myers Squibb confirmed that it paused autoimmune-disease studies of zolacabtagene autoleucel after life-threatening inflammatory and…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Genentech / Astex | Breast Cancer Discovery Collaboration Amid gRED Restructuring
Sobi Licenses Lacutamab in $580 Million Deal
Neomorph – $100M Molecular Glue Financing
Dyne Seeks $300 Million After BLA Acceptance